Mesenchymal Stem Cells for Tissue Engineering and Modelling

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Regenerative Engineering".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 6945

Special Issue Editors

1. Faculty of Medicine, Lomonosov Moscow State University, 119192 Moscow, Russia
2. Institute for Regenerative Medicine, Medical Research and Education Centre, Lomonosov Moscow State University, 119192 Moscow, Russia
Interests: regenerative medicine; wound healing; stem cell; tissue engineering; cell sheet; mesenchymal stem cell
Special Issues, Collections and Topics in MDPI journals
Laboratory of Cell Signaling Regulation, Moscow Institute of Physics and Technology, Dolgoprudny, Russia
Interests: regenerative medicine; synthetic biology; organ engineering

Special Issue Information

Dear Colleagues,

Advances in studies of mesenchymal stem/stromal cells (MSC) biology and application in regenerative medicine are tightly associated with their intrinsic properties involving participation in tissue physiological renewal and repair after damage. Furthermore, their ability to self-organize and pattern other cell types created an amazing opportunity for their application in tissue/organ engineering employing MSC ex vivo.

This Special Issue focuses on MSC use including, but not limited to the following topics:

  • Tissue engineering and artificial organs/scaffolds (including decellularized constructs)
  • Pre-clinical and clinical data on new MSC-based tissue engineering products
  • Patterning and differentiation potency of MSC in tissue-engineered constructs
  • Organoid assembly and self-organization of MSC to model tissues, organs or human disease
  • Bioprocess and manufacturing advances in tissue engineering products using human/animal MSC

We cordially invite original papers, review articles, letters and opinions to this Issue from experts in cell biology, regenerative medicine, manufacture, developmental biology and bioengineered fields.

Dr. Pavel Makarevich
Dr. Ilya Zubarev
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • MSC
  • tissue engineering
  • regenerative medicine
  • tissue modelling
  • self-organization

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 6475 KiB  
Article
Optimizing the Seeding Density of Human Mononuclear Cells to Improve the Purity of Highly Proliferative Mesenchymal Stem Cells
by Hiroyuki Nagai, Akihiro Miwa, Kenji Yoneda, Koichi Fujisawa and Taro Takami
Bioengineering 2023, 10(1), 102; https://doi.org/10.3390/bioengineering10010102 - 11 Jan 2023
Cited by 1 | Viewed by 2121
Abstract
Mesenchymal stem cells (MSCs) hold considerable promise for regenerative medicine. Optimization of the seeding density of mononuclear cells (MNCs) improves the proliferative and differentiation potential of isolated MSCs. However, the underlying mechanism is unclear. We cultured human bone marrow MNCs at various seeding [...] Read more.
Mesenchymal stem cells (MSCs) hold considerable promise for regenerative medicine. Optimization of the seeding density of mononuclear cells (MNCs) improves the proliferative and differentiation potential of isolated MSCs. However, the underlying mechanism is unclear. We cultured human bone marrow MNCs at various seeding densities (4.0 × 104, 1.25 × 105, 2.5 × 105, 6.0 × 105, 1.25 × 106 cells/cm2) and examined MSC colony formation. At lower seeding densities (4.0 × 104, 1.25 × 105 cells/cm2), colonies varied in diameter and density, from dense to sparse. In these colonies, the proportion of highly proliferative MSCs increased over time. In contrast, lower proliferative MSCs enlarged more rapidly. Senescent cells were removed using a short detachment treatment. We found that these mechanisms increase the purity of highly proliferative MSCs. Thereafter, we compared MSCs isolated under optimized conditions with a higher density (1.25 × 106 cells/cm2). MSCs under optimized conditions exhibited significantly higher proliferative and differentiation potential into adipocytes and chondrocytes, except for osteocytes. We propose the following conditions to improve MSC quality: (1) optimizing MNC seeding density to form single-cell colonies; (2) adjusting incubation times to increase highly proliferative MSCs; and (3) establishing a detachment processing time that excludes senescent cells. Full article
(This article belongs to the Special Issue Mesenchymal Stem Cells for Tissue Engineering and Modelling)
Show Figures

Figure 1

Review

Jump to: Research

18 pages, 851 KiB  
Review
Intraoperative Creation of Tissue-Engineered Grafts with Minimally Manipulated Cells: New Concept of Bone Tissue Engineering In Situ
by Olga A. Krasilnikova, Denis S. Baranovskii, Anna O. Yakimova, Nadezhda Arguchinskaya, Anastas Kisel, Dmitry Sosin, Yana Sulina, Sergey A. Ivanov, Peter V. Shegay, Andrey D. Kaprin and Ilya D. Klabukov
Bioengineering 2022, 9(11), 704; https://doi.org/10.3390/bioengineering9110704 - 17 Nov 2022
Cited by 8 | Viewed by 2087
Abstract
Transfer of regenerative approaches into clinical practice is limited by strict legal regulation of in vitro expanded cells and risks associated with substantial manipulations. Isolation of cells for the enrichment of bone grafts directly in the Operating Room appears to be a promising [...] Read more.
Transfer of regenerative approaches into clinical practice is limited by strict legal regulation of in vitro expanded cells and risks associated with substantial manipulations. Isolation of cells for the enrichment of bone grafts directly in the Operating Room appears to be a promising solution for the translation of biomedical technologies into clinical practice. These intraoperative approaches could be generally characterized as a joint concept of tissue engineering in situ. Our review covers techniques of intraoperative cell isolation and seeding for the creation of tissue-engineered grafts in situ, that is, directly in the Operating Room. Up-to-date, the clinical use of tissue-engineered grafts created in vitro remains a highly inaccessible option. Fortunately, intraoperative tissue engineering in situ is already available for patients who need advanced treatment modalities. Full article
(This article belongs to the Special Issue Mesenchymal Stem Cells for Tissue Engineering and Modelling)
Show Figures

Graphical abstract

25 pages, 1764 KiB  
Review
Mesenchymal Stem Cells and MSCs-Derived Extracellular Vesicles in Infectious Diseases: From Basic Research to Clinical Practice
by Natalia Yudintceva, Natalia Mikhailova, Viacheslav Fedorov, Konstantin Samochernych, Tatiana Vinogradova, Alexandr Muraviov and Maxim Shevtsov
Bioengineering 2022, 9(11), 662; https://doi.org/10.3390/bioengineering9110662 - 08 Nov 2022
Cited by 12 | Viewed by 2192
Abstract
Mesenchymal stem cells (MSCs) are attractive in various fields of regenerative medicine due to their therapeutic potential and complex unique properties. Basic stem cell research and the global COVID-19 pandemic have given impetus to the development of cell therapy for infectious diseases. The [...] Read more.
Mesenchymal stem cells (MSCs) are attractive in various fields of regenerative medicine due to their therapeutic potential and complex unique properties. Basic stem cell research and the global COVID-19 pandemic have given impetus to the development of cell therapy for infectious diseases. The aim of this review was to systematize scientific data on the applications of mesenchymal stem cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) in the combined treatment of infectious diseases. Application of MSCs and MSC-EVs in the treatment of infectious diseases has immunomodulatory, anti-inflammatory, and antibacterial effects, and also promotes the restoration of the epithelium and stimulates tissue regeneration. The use of MSC-EVs is a promising cell-free treatment strategy that allows solving the problems associated with the safety of cell therapy and increasing its effectiveness. In this review, experimental data and clinical trials based on MSCs and MSC-EVs for the treatment of infectious diseases are presented. MSCs and MSC-EVs can be a promising tool for the treatment of various infectious diseases, particularly in combination with antiviral drugs. Employment of MSC-derived EVs represents a more promising strategy for cell-free treatment, demonstrating a high therapeutic potential in preclinical studies. Full article
(This article belongs to the Special Issue Mesenchymal Stem Cells for Tissue Engineering and Modelling)
Show Figures

Figure 1

Back to TopTop